AccenGen Therapeutics, Inc. is an early-stage pharmaceutical company based in San Francisco, CA, dedicated to the research and development of novel, first-in-class medications for human health. With a focus on soluble epoxide hydrolase (sEH) inhibitors and dual sEH COX inhibitors, the company aims to address indications with fibrotic etiologies and the highest unmet needs, prioritizing the treatment of pulmonary fibrosis, a disease considered more severe than many cancers.
Utilizing their sEH core technology platform, AccenGen Therapeutics offers a range of product opportunities and diversified risk, supported by a wealth of scientific research with over 800 publications in top-tier peer-reviewed journals. Committed to making a significant impact on human health, the company's innovative approach holds promise for improving the lives of individuals affected by debilitating fibrotic conditions.
Generated from the website